You are here : Home > Research Entities > Medicines and healthcare techn ... > Pharmacology and Immunoanalysi ... > Technological Innovations for Detection and Diagnosis Laboratory

Laboratory | Biodetection | Mass spectrometry


Li2D

Technological Innovations for Detection and Diagnosis Laboratory

 

​​FRENCH

 

Published on 27 June 2018

​​The mission of the Technological Innovations for Detection and Diagnosis Laboratory (LI2D), based on the CEA site of Marcoule, is to develop methodologies and technologies for the detection of pathogens or toxic substances found in the environment or in biological samples / tissues and the discovery and validation of biomarkers for diagnosis. The aim of his research is to support the regional and national industrial fabric by promoting the transfer of innovations and reagents.

 


Team Leader
Laurent Bellanger 
04.66.79.64.67 
laurent.bellanger@cea.fr ​



The research carried out at Li2D is based on his expert knowledge in microbiological, immunological, genetic, genomic, proteomic, bioinformatics and high-resolution mass spectrometry techniques. This leads to the creation of reagents for targeted detection, such as monoclonal or polyclonal antibodies, for the development of rapid immunoassays (test strips or "detector tickets") or enzyme-linked immunosorbent assays (ELISA). For example, rapid assays have been designed for the detection of toxic marine algae, highly pathogenic bacteria, and more recently, Li2D has developed the Ebola eZYSCREEN® for rapid diagnosis in the field of Ebola virus. Probes and nucleotide primers development provides the development of specific and high-sensitivity detection assays (qPCR) based on the amplification of nucleotide sequences of the genome of microorganisms. The laboratory conducts these research to the pre-industrial stage. In the field of diagnosis without a priori  in microbiology, researchers of Li2D recently proposed a new technology, phylopeptidomic, allowing the quick identification of all pathogenic biological agents in mixture and to quantify by high resolution mass spectrometry. The potential of this technology has been validated in national exercises aimed at the identification of highly pathogenic microorganisms in complex environments. The mastery of high-resolution mass spectrometry technologies for the analysis of proteins and massive sequencing approaches of genomes has also provided the development of new concepts of proteogenomics and opens the possibility of several applications including the analysis of complex microbiota.

The laboratory has been ISO9001 certified since 2003, guaranteeing experimental rigor, quality management of technical platforms, project traceability and cost and time management.